




**Figure S1.** Related to Figure 1; PHGDH expression does not alter circulating serine levels or apoptotic cell death in *Braf<sup>CA</sup>; PTEN<sup>-/-</sup>* melanoma-bearing mice. **(A)** Schematic showing the serine synthesis pathway from glucose and how serine contributes to biomass in cells. PHGDH, phosphoglycerate dehydrogenase; PSAT1, phosphoserine amino transferase 1; PSPH, phosphoserine phosphatase; SHMT1/2, serine hydroxymethyltransferase 1/2; THF, tetrahydrofolate. **(B)** Plasma serine concentration in C57BL/6J mice, control *Braf<sup>CA</sup>; PTEN<sup>-/-</sup>* mice bearing melanomas, and PHGDH<sup>tetO</sup> *Braf<sup>CA</sup>; PTEN<sup>-/-</sup>* mice bearing melanomas as measured by GC/MS. Plasma from tumor bearing mice was collected 1 month after tumor induction. There is no statistically significant difference in plasma serine concentration between control and PHGDH<sup>tetO</sup> tumor bearing mice based on an unpaired, two-tailed Welch's t test with a p-value of 0.7330. n = 3 mice for control and PHGDH<sup>tetO</sup> mice and n = 5 for C57BL/6J mice. **(C)** Kaplan-Meier plot showing survival of control and PHGDH expressing (PHGDH<sup>tetO</sup>) mice bearing *Braf<sup>CA</sup>; PTEN<sup>-/-</sup>* tumors as described in Figure 1, with survival of animals separated by gender. **(D)** Representative immunohistochemistry staining and quantitation of cleaved caspase 3 (CC3) in the same *Braf<sup>CA</sup>; PTEN<sup>-/-</sup>* melanomas analyzed in Figure 1H that arose in mice without (control) or with (PHGDH<sup>tetO</sup>) a PHGDH transgene. Images were obtained at 10x magnification, scale bar = 300 µm. CC3 staining was quantitated by scoring 300 cells as CC3 positive or negative for each of 5 tumors of each genotype. No statistically significant difference was observed based on a Welch's t test that yielded a p value of 0.9094. Values represent the mean +/- SD.



**Figure S2.** Related to Figure 1; End stage *BRCA<sup>fl/fl</sup>; Trp53<sup>+/-</sup>* breast tumors have similar rates of proliferation and apoptosis regardless of PHGDH<sup>tetO</sup> status. (A) Species specific RT-qPCR for human (huPHGDH) and mouse (msPHGDH) PHGDH in *BRCA<sup>fl/fl</sup>; Trp53<sup>+/-</sup>* breast tumors described in Figure 2. The difference in huPHGDH expression is statistically significant with  $p = 0.0497$  by an unpaired, two-tailed Welch's t test, and the difference in msPHGDH expression is not statistically significant, with  $p = 0.1101$  by an unpaired, two-tailed Welch's t test.  $n=10$  tumors per genotype (B) Representative immunohistochemistry staining for Ki67 in control and PHGDH<sup>tetO</sup> *BRCA<sup>fl/fl</sup>; Trp53<sup>+/-</sup>* breast tumors. Images were obtained at 20x magnification, scale bar = 100  $\mu\text{m}$ . Ki67 staining in an area of 1.5 mm by 0.7 mm was quantitated for 5 tumors of each genotype, and no statistically significant difference was observed based on a Welch's t test that yielded a p value of 0.6598. (C) Representative immunohistochemistry staining for cleaved caspase 3 (CC3) in control and PHGDH<sup>tetO</sup>; *BRCA<sup>fl/fl</sup>; Trp53<sup>+/-</sup>* breast tumors. Images were obtained at 20x magnification, scale bar = 100  $\mu\text{m}$ . CC3 staining was quantitated by scoring 300 cells as CC3 positive or negative for each of 5 tumors of each genotype. No statistically significant difference was observed based on a Welch's t test that yielded a p value of 0.7345. For all panels, the values represent the mean  $\pm$  SD.



**Figure S3.** Related to Figure 3; Dependence on dietary serine for tumor growth is negatively correlated with both PHGDH expression level and tissue serine levels. (A) Breast cancer cells from an autochthonous *BRCA<sup>fl/fl</sup>; Trp53<sup>+/-</sup> MMTV-Cre* breast tumor with either a non-targeting sgRNA (sgctrl), or an sgRNA targeting PHGDH (sgPHGDH-1, sgPHGDH-2) were injected into the mammary fat pad of female NSG mice. Western blot analysis of PHGDH expression in tumors derived from these mice is shown. (B) Measurement of the tumor size over time in mice fed the specified diets, for tumors derived from injecting *BRCA<sup>fl/fl</sup>; Trp53<sup>+/-</sup> MMTV-Cre* breast tumor cells with either a non-targeting sgRNA (sgctrl) or an sgRNA targeting PHGDH (sgPHGDH-2) into the mammary fat pad of female NSG mice. There was a statistically significant difference in final tumor volume between mice fed -ser/gly and control diets based on an unpaired, two-tailed Welch's t test which yielded a p value of 0.0345. n=5 mice on each diet. (C) Concentration of the essential amino acids leucine and valine in control tumors (sgctrl) compared to PHGDH knockdown tumors (sgPHGDH-1) as measured by GC/MS. There was no statistically significant change in leucine or valine concentration based on an unpaired, two-tailed Welch's t test that produced p values of 0.7919 for leucine and 0.5803 for valine. n=4 tumors for each genotype. (D) LC/MS measurement of total ion counts (TIC) of serine normalized to tumor weight in control (sgctrl) and PHGDH knockdown (sgPHGDH-1) mammary fat pad orthotopic tumors formed from murine cell lines in mice fed either a -ser/gly diet or a high serine diet. No statistically significant change in serine levels were detected between sgctrl tumors fed a -ser/gly diet or a high serine diet as determined by an unpaired, two-tailed Welch's t test that yielded a p value of 0.8208. There was a statistically significant difference in serine levels between sgPHGDH-1 tumors in mice fed either a -ser/gly diet or a high serine diet as determined by an unpaired, two-tailed Welch's t test that yielded a p value of 0.0134. n = 4 tumors for each genotype. (E) Total serine amount measured in tissues from C57BL/6J mice by GC/MS normalized to tissue weight. n = 4 mice for each tissue. (F) Kaplan-Meier plot showing survival of NSG mice for which the same number of control (sgctrl) or PHGDH knockdown (sgPHGDH-1) cells derived from autochthonous breast tumors were implanted into the pancreas. There was no statistically significant difference in survival based on a Mantel-Cox log-rank test with a p-value of 0.1050. n = 5 mice per condition. For all panels, the values represent the mean +/- SD.



**Figure S4.** Related to Figure 4; **(A)** Western blot of MDA-MB-231 breast cancer cell lines with an empty vector control (+EV), PHGDH (+PHGDH), or PHGDH with an R236E mutation (PHGDH R236E) cultured *in vitro*. **(B)** Fraction of <sup>13</sup>C-labeled serine (fully labeled, M+3) in control (+EV) or PHGDH expressing (+PHGDH) MDA-MB-231 cells cultured in U-<sup>13</sup>C glucose as measured by GC/MS. There is a statistically significant difference in the fraction of glucose-derived serine between the cell types with a p-value of 0.0130 derived from an unpaired, Welch's t test. **(C)** Western blot of PHGDH expression in empty vector control (+EV) and PHGDH expressing (+PHGDH) MDA-MB-231 mammary fat pad orthotopic tumors. **(D)** Empty vector control (+EV) or PHGDH R236E expressing (+PHGDH R236E) MDA-MB-231 breast cancer cells were injected into the mammary fat pad of female NSG mice fed a control diet. Tumor size over time is shown. n=5 mice for each genotype. **(E)** GC/MS measurement of glycine concentration in empty vector control (EV) and PHGDH expressing (+PHGDH) MDA-MB-231 mammary fat pad orthotopic tumors. No statistically significant change in glycine concentration was detected as determined by an unpaired, two-tailed Welch's t test that yielded a p value of 0.7330. **(F)** Amount of α-ketoglutarate in empty vector control (EV) and PHGDH expressing (+PHGDH) MDA-MB-231 mammary fat pad orthotopic tumors in mice fed either a -ser/gly diet, a control diet, or a high serine diet as measured by LC/MS. No statistically significant change in α-ketoglutarate levels were detected between +EV and +PHGDH tumors as determined by unpaired, two-tailed Welch's t tests that yielded p values of 0.9965, 0.1356, and 0.7359, respectively. **(G)** Amount of 2-hydroxyglutarate in empty vector control (EV) and PHGDH expressing (+PHGDH) MDA-MB-231 mammary fat pad orthotopic tumors in mice fed either a -ser/gly diet, a control diet, or a high serine diet as measured by LC/MS. No statistically significant change in 2-hydroxyglutarate levels were detected between +EV and +PHGDH tumors as determined by unpaired, two-tailed Welch's t tests that yielded p values of 0.0726, 0.2707, and 0.4290, respectively. n=5 tumors for each genotype for **(E)**, **(F)**, and **(G)**. For all panels, the values represent the mean +/- SD.



**Table S2.** Related to STAR Methods; Nutrient composition of serine diets.

Nutrient	Serine and glycine free diet (g/kg)	Control diet (g/kg)	High serine diet (g/kg)
L-Alanine	3.5	3.5	3.5
L-Arginine HCl	12.1	12.1	12.1
L-Asparagine	6.0	6.0	6.0
L-Aspartic Acid	3.5	3.5	3.5
L-Cystine	3.5	3.5	3.5
L-Glutamic Acid	40.0	40.0	40.0
Glycine	0	23.3	23.3
L-Histidine HCl, monohydrate	4.5	4.5	4.5
L-Isoleucine	8.0	8.0	8.0
L-Leucine	12.0	12.0	12.0
L-Lysine HCl	18.0	18.0	18.0
L-Methionine	8.2	8.2	8.2
L-Phenylalanine	7.5	7.5	7.5
L-Proline	3.5	3.5	3.5
L-Serine	0	3.5	20.0
L-Threonine	8.2	8.2	8.2
L-Tryptophan	1.8	1.8	1.8
L-Tyrosine	5.0	5.0	5.0
L-Valine	8.0	8.0	8.0
Sucrose	100.0	100.0	100.0
Corn Starch	407.88	381.18	364.58
Maltodextrin	150.0	150.0	150.0
Soybean Oil	80.0	80.0	80.0
Cellulose	50.0	50.0	50.0
Mineral Mix, AIN-93M-MX (94049)	35.0	35.0	35.0
Calcium Phosphate, monobasic, monohydrate	8.2	8.2	8.2
Vitamin Mix, AIN-93-VX (94047)	13.0	13.0	13.0
Choline Bitartrate	2.5	2.5	2.5
TBHQ, antioxidant	0.02	0.02	0.02